Thursday, April 10, 2014
University of California, Los Angeles
researchers have treated glioblastoma in mice by inhibiting epithelial
membrane protein 2.1 The findings open up a new
indication for spinout Paganini Biopharma Inc.,
which has a mAb against the target in development for triple-negative breast
Safe harbor upstream
Wadehra told SciBX that EMP2 inhibitors could
treat cancer with fewer side effects than inhibitors of the CD51/CD61-FAK-Src
pathway. She said that the latter three targets are widely expressed by normal
cells, whereas EMP2 is highly expressed in GBM and other tumors and has
limited expression in normal tissue.
Haas, M.J. SciBX 7(14); doi:10.1038/scibx.2014.389 Published online
April 10, 2014
1. Qin, Y. et al. J. Biol. Chem.; published online March 18,
Contact: Madhuri Wadehra, University of California,
Los Angeles David Geffen School of Medicine, Los Angeles, Calif.
2. Wadehra, M. et al. J. Biol. Chem. 277, 41094-41100 (2002)
3. Wadehra, M. et al. Exp. Mol. Pathol.
74, 106-112 (2003)
4. Wadehra, M. et al. Cancer 107, 90-98 (2006)
5. Habeeb, O. et al. Cancer 116,
6. Fu, M. et al. Clin. Cancer Res. 16, 3954-3963 (2010)
7. Fu, M. et al. Mol. Cancer Ther.; published
online Jan. 21, 2014; doi:10.1158/1535-7163.MCT-13-0199
8. Freije, W.A. et al. Cancer Res. 64, 6503-6510 (2004)
AND INSTITUTIONS MENTIONED
Paganini Biopharma Inc., Encino, Calif.
University of California, Los Angeles, Calif.
University of California, Los Angeles, David Geffen School
Los Angeles, Calif.
University of California, Los Angeles, Jonsson
Comprehensive Cancer Center, Los Angeles, Calif.
University of California, San Diego, La Jolla, Calif.